



Research Article

Analysis of Endostatin Levels in Early Onset Preeclampsia, Late onset Preeclampsia and normal Pregnancy

Analisis Kadar Endostatin Pada Preeklamsi Awitan Dini, Preeklamsi Awitan Lambat dan Hamil Normal

Yusrawati, Aldina Ayunda Insani, Nuzulia Irawati

Department of Obstetrics and Gynecology

Medical Faculty of Andalas University/

Dr. M. Djamil Hospital

Padang

Abstract

Objective: The purpose of this research is to analyze the difference between the mean serum levels of endostatin in early onset preeclampsia (EOPE), late onset preeclampsia (LOPE) and normal pregnancy.

Method: This research design was an analytic cross-sectional observation on 80 pregnant women with EOPE, LOPE and normal pregnancy with matched gestational age in M. Djamil hospital, Reksodiwiry hospital, Bhayangkara hospital, Rasidin Padang hospital, and Anak Air of Public Service, from July to November 2015. Samples were selected based on consecutive sampling. Blood was collected intravenously, centrifuged and endostatin serum measured by ELISA method in the Laboratory of Biomedical Faculty of Medicine Andalas University. Normality test data with Shapiro-Wilk, unpaired t-test independent for mean difference, using SPSS.

Result: The mean levels of endostatin in the EOPE group and normal pregnancy group is 125 ± 49.3 ng/ml and 90.8 ± 28.3 ng/ml ($p < 0.05$), in the LOPE group and normal pregnancy group is 86.2 ± 21.8 ng/ml and 78.3 ± 19.5 ng/ml ($p > 0.05$) and finally in the EOPE group and LOPE group is 125 ± 49.3 ng/ml and 86.2 ± 21.8 ng/ml ($p < 0.05$).

Conclusion: The mean levels of endostatin in the PE group is higher than normal pregnancy. The mean levels of endostatin in the EOPE group is higher than LOPE group.

This Paper will also be published in Indonesian in The Jurnal Kesehatan Andalas. 2016

Key words: endostatin, early onset severe preeclampsia, late onset severe preeclampsia

Correspondence: Yusrawati. Department Of Obstetrics and Gynecology, Dr. M. Djamil Hospital. Jl. Perintis Kemerdekaan, Padang. Telephone : 0811668272, Email: yusrawati_65@yahoo.co.id

Abstrak

Tujuan: Tujuan

penelitian ini adalah menganalisis kadar endostatin antara preeklamsi awitan dini (PEAD), preeklamsi awitan lambat (PEAL) dan hamil normal.

Metode: Desain penelitian adalah cross sectional terhadap 80 ibu hamil (PEAD, PEAL dan hamil normal) dengan usia kehamilan sama dengan kelompok PEAD dan normal untuk kelompok PEAL di RSUP dr. M. Djamil, RS. Tingkat III dr. Reksodiwiry, RS. Bhayangkara, RSUD. Dr. Rasidin, dan Puskesmas Anak Air Padang, Juli-November 2015. Sampel berdasarkan consecutive sampling. Darah intravena sampel, disentrifuge, didapatkan serum dan diukur dengan metode ELISA di Laboratorium Biomedik FK- UNAND. Uji normalitas data dengan Shapiro Wilk, bedaradengan uji t tidak berpasangan, dan diolah menggunakan SPSS.

Hasil: Rerata kadar endostatin kelompok PEAD dengan hamil normal adalah $125 \pm 49,3$ ng/ml dan $90,8 \pm 28,3$ ng/ml ($p < 0,05$), kelompok PEAL dengan hamil normal adalah $86,2 \pm 21,8$ ng/ml dan $78,3 \pm 19,5$ ng/ml ($p > 0,05$) dan kelompok PEAD dengan PEAL adalah $125 \pm 49,3$ ng/ml dan $86,2 \pm 21,8$ ng/ml ($p < 0,05$).

Kesimpulan: Rerata kadar endostatin PE lebih tinggi dari pada hamil normal. Rerata kadar endostatin PEAD lebih tinggi dari pada PEAL.

Penelitian ini juga akan dipublikasikan di Jurnal Kesehatan Universitas Andalas. 2016

Kata kunci: Endostatin, Preeklamsi Awitan Dini, Preeklamsi Awitan Lambat



INTRODUCTION

Preeclampsia (PE) is one of the major problems in pregnancy that can cause maternal mortality being a factor in 10-15% of all maternal deaths worldwide.¹ The frequency of this condition varies from country to country.²

5-8% of pregnancies in USA are affected by this condition and it was the cause of 20% of the maternal deaths in Canada in 1999–2000.³ High blood pressure caused 30% of all maternal deaths in Indonesia in 2010, and 3–10% of these involved preeclampsia.⁴ About 45% of maternal deaths in West Sumatera are related to high blood pressure, preeclampsia and eclampsia. According to figures from Dr. M Djamil hospital preeclampsia is an increasing problem with 5.5% in 1998-2002,⁵ 8.3% in 2011, 11.5% in 2012 and 12.% in 2013.⁶

Preeclampsia can cause two different conditions depending on the stage of pregnancy. In the first 34 weeks of pregnancy EOPE is related to failure of trophoblast invasion and remodelling of spiral arteries in the uterus. LOPE after the 34 week mark, is caused by an increase in maternal blood vessel inflammation in a previously normal pregnancy or atherosclerosis of a placenta that less elastic was previously developing normally.

The pathogenesis of PE begins when the angiogenic and antiangiogenic factors in the placenta are out of balance.^{7,8} One antiangiogenic factor, endostatin, is a product of collagen XVIII with a C terminal and a

molecular weight of 20 kDa. It causes endothelial cell apoptosis,⁸ inhibits cell proliferation and migration. In some studies, the level of endostatin has been observed to be elevated in women with severe preeclampsia.^{9,10} Other studies report no increase in levels in normal pregnancy indicating that the placenta is not contributing to serum concentration of endostatin. No clinically significant difference has been observed between preoxidised lipid levels in PE or normal pregnancy.¹¹ As a result of this controversy it was decided to conduct this study to establish the difference in mean levels of endostatin between EOPE and normal pregnancy, LOPE and normal pregnancy and between EOPE and LOPE.

METHOD

This study design was an analytic cross-sectional observation in dr. M. Djamil hospital, dr. Reksodiwiryono hospital, Bhayangkara hospital, dr. Rasidin Padang hospital, and Anak Air of community health clinic, from July to November 2015. Ethical approval no. PE.27.2015 for the research was obtained from the ethical committee for research at dr. M. Djamil hospital.¹² The population studied was all women who were 20 weeks or more pregnant who were treated as outpatients or admitted to delivery wards in these hospitals whether they had a normal pregnancy, EOPE or LOPE. Each PE sample was matched with a sample with normal pregnancy and similar gestational age.



Three ml blood samples were taken from the antecubital area by the technician in the delivery ward or midwifery clinic. These samples were placed in a vacutainer containing 2.5 ml ethylenediaminetetraacetic acid (EDTA) and centrifuged at 2000-3000 rpm. The serum was stored at -80 °C in the Andalas University Biomedic laboratory in Padang. A 0,5ml sampel of the blood was placed in another vacutainer without EDTA for Hb and Leukocyte levels at the blood testing clinic.

Endostatin levels were measured using a Ray Bio Tech ELISA kit in the Andalas University Biomedic laboratory. Data obtained was analysed using the unpaired t test.

RESULT


Table 1. Characteristics of the women in the <34 week gestation age sample

Characteristic	EOPE (Mean±SD)	Normal (Mean±SD)	P
Age (years)	32.5±7.0	30.0±4.1	0,179
BMI before pregnancy (kg/m ²)	23.5±1.8	22.8±2.1	0,246
Hb levels (gr/dl)	11.3±1.5	10.8±0.9	0,220
Leukocyte count (m ³)	13373.6±4829.8	8105.0±1451.5	0,000


Table 2. Characteristics of the women in the >34 week gestation age sample

Characteristic	LOPE		Normal		P
	Mean ±SD	Me (Min-Max)	Mean ±SD	Me (Min-Max)	
Age (years)	31.2 ± 7.3		30.0 ± 5.4		0,559
BMI before pregnancy (kg/m ²)	25.3 ± 2.3		23.1 ± 2.9		0,012
Hb levels (gr/dl)	11.5 ± 1.6		10.6 ± 1.1		0,655
Leukocyte count (m ³)		13305 (8400-24700)		8325 (5400-9900)	


Graphic 1. Distribution of Parity for Each Group



Graphic 2. Distribution of History of Preeclampsia for Each Group



Graphic 3. Distribution of History of Hypertension for Each Group



Graphic 4. Distribution of History of Diabetes Mellitus for Each Group




Table 3. Average Level of Endostatin for Each Group



Gestational Age	Endostatin Levels (ng/mL)		P
	Mean	SD	
<34 weeks			
EOPE	125.1	49.3	0,011*
Normal	90.8	28.3	
≥34 weeks			
LOPE	86.2	21.8	0,237
Normal	78.3	19.5	
Severe PE			
EOPE	125.1	49.3	0,003*
LOPE	86.2	21.8	

(* difference is statistically significant)

DISCUSSION

Difference in average Endostatin levels between EOPE and normal pregnancy

The average level of endostatin amongst EOPE subjects was 125.1 ng/ml compared to 90.8ng/ml for women with normal pregnancy. This difference of 34.3 ng/ml with a 95% confidence interval of 8.4-60.3ng/ml and $p=0.011$ is statistically significant (at the 95% level).

There is a significant increase in endostatin concentrations in PE patients compared with those with normal pregnancies from early pregnancy,¹³ and a high level of endostatin at gestation age 16-20 weeks indicates a higher risk of developing PE.¹⁴

During pregnancy, extravillous trophoblast (EVT) establishes uteroplacental circulation by invading the decidua and spiral arteries¹⁵ beginning with the process of differentiation of the villi in the placenta, proliferation of cells invading the extracellular matrix (ECM), requiring a focal adhesion that is mediated by tyrosine kinase that is the focal adhesion kinase (FAK).¹⁶

The invasion of EVT is controlled by stimulation from pro angiogenesis, *tumor growth factor-β 1-3 (TGFB 1-3)*, *tissue inhibitor metalloproteinase (TIMP)*, and *plasminogen activator inhibitor (PAI-1 and 2)*. If an imbalance occurs between factors and the ECM like endostatin, it will contribute to a pathological disturbance of pregnancy such as preeclampsia.¹⁵

Endostatin is bound to several membrane proteins such as integrin $\alpha 5\beta 1$, integrin $\alpha v\beta 3$,¹⁷ inhibiting the activation of cellular signaling components including FAK and *extracellular regulated kinase (ERK)*. Endostatin depresses *insulin growth factor-II (IGF-II)*- induces FAK Phosphorylation, protein kinase B/mammalian target of rapamycin (mTOR), P70S6 Kinase (S6K) and activation of ERK1/2.^{15,17}

Endostatin inhibits FGF and VEGF, migration of human microvascular endothelial cells and influences the formation of blood vessels in the embryo.¹⁸ Endostatin is also known to control migration and proliferation of cells like phospholipase C- γ (PLC- γ), PKB, p44/42, *mitogen activated protein kinase (MAPK)*, p38 MAPK and *p21-activated kinase (PAK)* via the intracellular pathway.

One EOPE patient had the highest endostatin level (200,02ng/ml) measured. On average this group were nulliparous with gestation age was 29-30 weeks, had Hb levels of 15,3 gr/dl, a leukocyte count of 21800 m³, blood pressure 170/130 mmHg and proteinuria +2.

One mechanism that may influence the increase in high endostatin levels in this group is immune maladaptation. In nulliparous EOPE mothers, there is inadequate production of blocking antibodies for the trophoblast to be protected. Furthermore there is a reduction in the expression of Human Leucocyte Antigen-G (HLA-G) in the cytotrophoblast resulting in a reduction in the protection of the trophoblast from destruction from natural killer (NK) and cytotoxic cytokines interleukin-2 (IL-2) inhibiting the trophoblast invasion of the spiral arteries. For nulliparous particularly, conception that happens too quickly after the exposure to sperm does not allow sufficient time for the mother to produce *blocking antibodies*.¹⁹

High maternal Hb levels will influence in vivo vascular resistance, Hb in red blood cells can



inhibit *endothelium dependent vasodilatation* so that an increase in hemoglobin concentration of 1 gm/dl can reduce the production of *Nitric Oxide* (NO).

It is known that NO plays a role in the migration of endotel cells induces *VascularEndothelial Growth Factor*(VEGF) important in increasing proliferation, migrasion and survival of endotel cells along with increasing the permeability of the capillaries. As embrio cells need oxygen as a source of energy for molecular processes, VEGF has an important role in the vasculogenesis and angiogenesis of the embryo. Damage to a single VEGF allele will result in abnormal blood vessels including those in the placenta resulting in embryo death at 10 to 12 days. 20

Endostatininterfers with the bonding process between VEGF and Kinase insert domain receptor (KDR/Fik 1/VEGFR2). KDR/Fik1/VEGFR2 is a VEGF receptor in endotel vascular cells. The binding of endostatinwith KDR/Fik1/VEGFR2 therefore will cause an increase in free VEGF that is then unable to function. The process of vasculogenesis and angiogenesis will be inhibited resulting in lack of blood vessels formation and blood flow..^{9,20}

Difference in Average Endostatin Levels Between LOPE and Normal Pregnancy

The average value of endostatin for LOPE patients was 86,2ng/ml compared to 78,3ng/ml for normal pregnancies, a difference of 7,9 (95% Confidence interval range 5,38-21,10) The value of $p=0,237$ ($p>0,05$) indicating that this difference is not statistically significant.

This lack of measurable difference could be a result of several factors that influence the function of endostatin like the growth factor that stimulates the proliferation of cells (fibroblast 2/ FGF2 or VEGF for example).²¹

This result differs from the findings of Mahmoudand Abdel Raouf (2006) who discovered significantly higher levels of endostatin and VEGF in PE patients compared to women with normal

pregnancies or women who were not pregnant. The level of endostatin in patients with severe preeclampsia was higher than those with mild PE irregardless of time of onset.

Endostatin binds to several membrane proteins, such as fibronectin $\alpha 5\beta 1$ receptor, and interacts with integrin $\alpha 5\beta 5$ dan $\alpha v\beta 3$. Endostatin also inhibits the binding sites endothelial cells and collagen type 1 (interstitial collagen).⁹

LOPE is influenced by extrinsic or maternal factors where specific conditions that increase the mass of the placenta such as diabetes or twins, or increases the surface area of the placenta like hypoxia from the mother or anemia will cause an excess of release of *syncytial knots*. Pregnant women with high maternal risk factors or inflammation reactions that are not in line with release of fragments of apoptosis trophoblast cause the inability of the maternal system to overcome the rise in apoptosis fragment numbers. Syncytial knots occur at 32 weeks. These two things in the end cause secondary necrosis in the blood that can trigger the clinical symptoms of LOPE.¹⁹

As this study was concerned with factors influencing the role of endostatin other than those related to the extrinsic or maternal factors discussed above, these women (anemia, diabetes, twins) were excluded from our sample. Hence the results from this study would not be expected to show the difference in average endostatin levels between LOPE and normal pregnancy observed in studies that included such patients.

Difference in average Endostatin levels between EOPE and LOPE

The average endostatin level in EOPE was 125,09ng/ml compared to 86,2ng/ml in LOPE; a difference of 38,9ng/ml (95% Confidence Interval 14.17-63.68). The result of the unpaired t test being $p=0,003$ ($p<0,05$) indicating that difference was statistically significant.

EOPE patients, but not LOPE patients, have



elevated endostatin levels compared to women with normal pregnancies. Endostatin is an antagonist factor for angiogenesis that has a wide ranging influence on the inhibition of the angiogenesis process that has not been widely studied.¹⁹

The evidence suggests an imbalance between placenta angiogenic and antiangiogenic factors exists with PE that can endanger the vascular endothel and give rise to clinical symptoms in the mother. The rise in endostatin levels that occurs in the first trimester is related to the risk of developing PE.¹³ Imbalance in the production of VEGF and endostatin is related to a number of conditions including systemic sclerosis, atherosclerosis as well as PE as it influences the cell proliferation, migration and apoptosis processes hence influencing morphogenesis and maturation of blood vessels.¹⁰

Studies on mice reveal that there is a pathological change in the placenta with EOPE which has a detrimental effect on the fetus and its development that does not appear to occur in LOPE.³³ Hence it has been concluded that while EOPE is related to perfusion of the uteroplacenta, LOPE is more often related to extrinsic factors like the larger size of the placenta or some systemic disease in the mother.²⁵

Experimental studies have indicated that there is a positive correlation between endostatin levels and proteinuria value ($p=0,663$) in patients with chronic kidney disease. Endostatin is related to duration of hypertension and vascular index, myocardium and organ damage that targets the kidneys.²⁶ This is explained by the increase in circulation of the level of endostatin increasing extracellular remodeling of the vascular network.²⁷ Endostatin will inhibit the functioning of VEGF-A, a factor in the development of the kidneys. VEGF-A protects the glomerulus capillary structure and the endothelial cell and the peritubular capillary damage repair processes so

inhibiting its function results in impaired renal function increasing the permeability of the basal membrane causing leakage and subsequent proteinuria.²⁸

EOPE subjects in this study had an average blood pressure of 167/111 mmHg compared to 174/113 mmHg in the LOPE group. It has previously been suggested that endostatin levels could be a marker for damage and remodeling of the extracellular matrix in a number of diseases. Long term hypertension induces remodeling of the cardiovascular extracellular matrix. In hypertension there is an induction of extracellular remodeling with the activation of metalloproteinase-2 and metalloproteinase-9 both of which play an important role in the degradation of collagen XVIII to endostatin.²⁶

There was no difference in Hb levels observed between the groups in this study except there were some extreme values of Hb levels in EOPE. Phalappan (2008) concludes that women with high levels of Hb are at risk of developing of PE also. Hence it is thought that there are no other risk factors that influence Hb levels such as patterns of iron levels in the diet, iron supplements or levels of ferritin that have not yet been studied.

In the EOPE group the highest leukocyte count measured ($21,800 \text{ m}^3$) and endostatin level 200 ng. One member of the LOPE group, produced a sample with the leukocyte count ($24,700 \text{ m}^3$) and endostatin level 84,3 ng.

Hypoxia in preeclampsia can activate leukocytes directly in intervillous space or can stimulate the production of lipid peroxide and proinflammatory cytokines by the placenta, which can in turn activate leukocytes as they move through the placental circulatory system. In PE patients there occurs a modulation of neutrophil which increases the superoxide anion production to levels above NO which can cause endothelial damage.



The inflammation processes involving leukocytes requires the function of adhesion molecules; the most important of these in the recruitment of leukocytes are selectins, integrins of the immunoglobulin superfamily. Selectin is a single transmembranepolipeptide expressed in the circulatory cells; endothelium and blood cells. These molecules are activated after induction. Three types of selectin molecules are involved; L - selectin in leukocytes , E - selectin and P - selectin in the endothelial cells , these later particularly in platelets . Early PMN adhesion is mediated by E selectin that is required for the antiangiogenic activity of endostatin.³⁰

Integrin, a transmembrane adhesion molecule is widely distributed in many cells. Endostatin binds to integrin αv on the surface of endothelial cells and influences the process of adhesion of leukocytes and *inhibits the process of angiogenesis. Endostatin binding to intergrinso an increase of endostatinis associated with functions by increase in number of leukocytes in the process of leukocyte adhesion and mediated by integrin.*¹⁷

The limits of this study is only to observe the average levels of endostatin as antiangiogenic factor, hence it is not possible to judge the importance of the imbalance of the VEGF receptor, FAK or other angiogenic factors related to metabolism or function of endostatin in endotel cells. The bonding of endostatin with intergrin or selectin, both important markers in the adhesion process of leukocytes were not studied either.

Conclusion

The results of this study show that the average level of endostatin in PE is higher than in normal pregnancy. The average value of endostatin in EOPE is higher than in LOPE.

THANKSFULL

The author is grateful to the head and staff of

Dr. M. Djamil general hospital, RS. Tingkat III Reksodiwiryo, RS. Bhayangkara, RSUD. Dr. RasedindanPuskesmas Anak Air Padang who have given permission for this research. The author expresses thanks to the head and staff of LaboratoriumBiomedik FK-Unand who analysed the samples.

REFERENCES

1. Cunningham F. Leveno KJ. Bloom LS. Hauth JC. Rouse DJ. & Spong CY. (editor). Williams Obstetrics 24rd edition. New York: The McGraw-Hills Companies. 2014.
2. Eastabrook G. Hu Y & Dadelszen PV. 2014. The Role of Decidual Natural Killer Cells in Normal Placentation and in the Pathogenesis of Preeclampsia. Journal Obstetric Gynecologic Clinical, 467-478 (diunduh 17 November 2014 tersedia dari http://www.jogc.com/abstracts/full/200806_Obstetrics_2.pdf)
3. Duley L. The Global Impact of Pre-eclampsia and Eclampsia. Seminars in Perinatology. 2005;33(3):130-137 (diunduh 17 November 2014 tersedia dari <https://www.researchgate.net/publication/26236123>)
4. Kemenkes. Profil Kesehatan Indonesia Tahun 2013. Sekretariat Jendral Kemenkes RI. Jakarta. 2014; ISBN 978-602-235-645-5.
5. Madi & Sulin. Angka Kematian Pasien Preeklampsia dan Eklampsia di RSUP Dr. M. Djamil Padang 1998-2002. Bagian Obstetri Gynekologi Fakultas Kedokteran Universitas Andalas/RSUP. Dr. M. Djamil. Padang: Kongres POGI XII. 2003.
6. _____. Laporan Kasus Preeklampsia dari Tahun 2010-2013. Padang: Medical Record RSUP. Dr. M. Djamil. 2013.



7. O'Reilly MS. Boehm T. Shing Y. Fukai N. Vasios G. Lane WS. et al. Endostatin : An Endogenous Inhibitor of Angiogenesis and Tumor Growth. *Cell*. 1997;88: 277-285 (diunduh 16 Januari 2015) tersedia dari <http://isites.harvard.edu/fs/docs/icb.topic557253.files/endostatin.pdf>
8. Dhanabal M. Ramchandran R. Waterman MJ. Lu H. Knebelmann B. Segal M. et al. Protein Chemistry and Structure: Endostatin Induces Endothelial Cell Apoptosis. *Journal Biological Chemistry*. 1999; 274: 11721-11726 (diunduh 17 November 2014) tersedia dari <http://www.jbc.org/content/274/17/11721.full.html#ref-list-1>
9. Kim YM. Hwang S. Kim YM. Pyun BJ. Kim TY. Lee ST. et al. Mechanisms of Signal Transduction : Endostatin Blocks Vascular Endothelial Growth Factor-mediated Signaling via Direct Interaction with KDR/Flk-1. *Journal Biological Chemistry*. 2002; 277: 27872-27879 (diunduh 17 November 2014) tersedia dari <http://www.jbc.org/content/277/31/27872.full.html#ref-list-1>
10. Wienhues-Thelen UH. Block D. & Huedig H. Endostatin as a Marker of Heart Failure. 2012; US/2012/0009610 A1, 1-18 (diunduh 6 November 2014) tersedia dari <http://www.faqs.org/patents/app/20120009610>
11. Hirtenlehner K. Polheimer J. Lichtenberger C. Wolschek MF. Zeisler H. Husslein P. et al. Elevated serum concentrations of the angiogenesis inhibitor endostatin in preeclamptic women. *J Soc Gynecol Investig*. 2003; 10(7): 412-7. (diunduh 17 November 2014) tersedia dari <http://www.ncbi.nlm.nih.gov/pubmed/14519482>
12. Panitia Etik Penelitian Kesehatan (PEPK) RSUP. Dr. M. Djamil Padang. Ethical Clearance. Padang. 2015
13. Thissier-Levy S. Boucoiran I. Luo ZC. Nuyt AM. Julien P. Fraser WD. et al. Endostatin Levels and the Risk of Subsequent Preeclampsia. *European Journal of Obstetrics and Gynecology and Reproductive Biology*. 2013; 170: 396-400 (diunduh 17 November 2014) tersedia dari <http://dx.doi.org/10.1016/j.ejogrb.2013.07.039>
14. Wathen KA. Pre-Eclampsia The Role of Soluble VEGF Receptor and Related Anti-angiogenic Factors Beyond. Disertasi. Finland: Faculty of Medicine, University of Helsinki. 2011; 42-44 (diunduh 18 November 2014) tersedia dari <https://helda.helsinki.fi/bitstream/handle/10138/26441/preeclam.pdf?sequence=1>
15. Polheimer J. Haslinger P. Fock V. Prast J. Saleh L. Biadasiewicz K. et al. Endostatin Suppresses IGF-II Mediated Signaling and Invasion of Human Extravillous Trophoblast. *Endocrinology Journals*. 2011; 152(11): 4431-4442 (diunduh 5 November 2014) tersedia dari <http://dx.doi.org/10.1210/en.2011-1196#sthash.Odrd1oJk.dpuf>
16. Macphee DJ. Mostachfi H. Han R. Lye SJ. Post M. Cannigia I. Focal Adhesion Kinase is a Key Mediator of Human Trophoblast Development. *Laboratory Investigation*. 2001; 81 (11): 1469-1483 (diunduh tanggal 16 Januari 2015) tersedia dari <http://www.ncbi.nlm.nih.gov/pubmed/11706056>
17. Rehn M. Veikkola T. Kukk-Valdre E. Nakamura H. Ilmonen M. Lombardo C. R. et al. Interaction of Endostatin With Integrins Implicated in Angiogenesis. *PNAS*. 2001; 98 (3): 1024-1029 (diunduh 16 Januari 2015) tersedia dari <http://www.pnas.org/cgi/doi/10.1073/pnas.031564998>
18. Eriksson K. Magnusson P. Dixelius J. Welsh LC. Cross MJ. Angiostatin and endostatin inhibit endothelial cell migration in response to FGF and VEGF without interfering with specific intracellular signal transduction pathways. *FEBS*



- Lett. 2003; 536: 19-24 (diunduh 16 Januari 2015) tersedia dari [http://doi:10.1016/S0014-5793\(03\)00003-6](http://doi:10.1016/S0014-5793(03)00003-6)
19. Winkstrom AK. Biochemical and Epidemiological Studies of Early-Onset dan Late-Onset Preeclampsia. In Digital Comprehensif Summaries From The Faculty of Medicine. 2009; 1-82 (diunduh tanggal 17 Januari 2014) tersediadari www.divaportal.org/smash/get/diva2:170891/FULLTEXT01.pdf
 20. Skovseth DK. Veuger MJ. Sorensen DR & Haraldsen PM. Endostatin Dramatically Inhibis Endothelial Cell Migration, Vascular Morphogenesis and Perivascular Cell Recruitment in Vivo. *Blood*. 2005; 1044-1051 (diunduh 17 Januari 2015) tersedia dari <http://www.bloodjournal.org/cgi/pmidlookup?view=long&pmid=15466935>
 21. Faye C. Chautard E. Olsen BR & Ricard-Blum S. The First Draft of the Endostatin Interaction Network. *Journal Biological Chemistry*. 2009; 284: 22041-22047 (diunduh 17 Januari 2015) tersedia dari <http://www.jbc.org/content/284/33/22041.full.html#ref-list-1>
 22. Sanchez-Aranguren L. Prada CE. Riano-Medina CE & Lopez M. Review Article : "Endothelial Dysfunction and Preeclampsia : Role of Oxidative Stress". *Frontiers in Physiology*. 2014; 5: 1-11 (diunduh 17 Januari 2015) tersedia dari <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4193194/doi:10.3389/fphys.2014.00372>
 23. Sasaki T. Hohenester E & Timpl R. Review Article: Structure and Function of Collagen-Derived endostatin Inhibitors of Angiogenesis. *Life*. 2002; 53: 77-84 (diunduh 17 Januari 2015) tersedia dari <http://www.ncbi.nlm.nih.gov/pubmed/12049199>
 24. Suppo LM. Bentlin MR & Trindade CEP. Preeclampsia : Effect on Fetus and Newborn. *Neoreviews*. 2011; 12(4) (diunduh 17 Januari 2015) tersedia dari <http://neoreviews.aappublications.org/content/12/4/e198>
 25. Eleazar S. Romero R. Kusanovic JP. Ogge G. Hussein Y. Yeo L. et al. Late Onset Preeclampsia is Associated with an Imbalance of Angiogenic and Anti Angiogenic Factors in Patients with and Without Placental lesions Consistent With Maternal Underperfusion. *The Journal of Maternal Fetal and Neonatal Medicine*. 2011. (diunduh 17 Januari 2015) tersedia dari <http://www.ncbi.nlm.nih.gov/pubmed/21867402>
 26. Carlsson AC. Ruge T. Sundstrom J. Ingelsson E. Larsson A. Lind L. et al. Association Between Circulating Endostatin, Hypertension Duration and Hypertensive Target-Organ Damage. *American Heart Association*. 2013; 62: 1146-1153 (diunduh 17 Januari 2015) tersedia dari <http://hyper.ahajournals.org/DOI:10.1161/HYPERTENSIONAHA.113.02250>
 27. Sund M. Xie L & Kalluri R. The Contribution of Vascular Membranes and Extracelular Matrix to The Mechanics of Tumor Angiogenesis. *APMIS*. 2004; 112: 450-462 (diunduh 17 Januari 2015) tersedia dari <http://www.ncbi.nlm.nih.gov/pubmed/15563309>
 28. Seko. Fukuda S & Nagai R. Serum Levels of Endostatin, Vascular Endothelial Growth Factor (VEGF) and Hepatocyte Growth Factor (HGF) in Patient With Acute Myocardial Infarction Undergoing Early Reperfusion Therapy. *Clinical Science*. 2004; 106: 439-442 (diunduh 20 Maret 2015) tersedia dari <http://www.ncbi.nlm.nih.gov/pubmed/14965340>
 29. Yu Y. Moulton KS. Khan MK. Vineberg S. Boye E. Davis VM. et al. E-Selectin is Required for The Antiangiogenic Activity of Endostatin. *PNAS*.



1ST World Congress on | LONDON April 24–26, 2017

MATERNAL FETAL NEONATAL MEDICINE

from periconception to early infancy | Queen Elizabeth II Conference Centre

Q E II CENTRE



2004; 101 (21) : 8005-8010 (diunduh 20 Maret 2015) tersedia dari

<http://www.ncbi.nlm.nih.gov/pubmed/15148373>

30. Schmidt A. Wenzel D. Ferring I. Kazemi S. Sasaki T. Hescheler J. et al. Influence of Endostatin of EmbrionicVasculo and Angiogenesis. Developmental Dynamics. 2004; 230: 468-480 (diunduh 20 Maret 2015) tersedia<http://www.ncbi.nlm.nih.gov/pubmed/15188432>